IBRX News

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misled on Drug Efficacy: Levi & Korsinsky

ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman

Securities Fraud Investigation Into ImmunityBio, Inc. (IBRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Securities Fraud Investigation Into ImmunityBio, Inc. (IBRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

IBRX Class Action Reminder: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ImmunityBio, Inc. Securities Fraud Class Action

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Reach Out

IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law

Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow by $1 Billion During 2026-2030 - Johnson & Johnson, Janssen Research & Development, and Merck & Co. Lead the Competition